Critical Care Medicine , Pulmonary and Critical Care Medicine, Sleep, Sleep Apnea, Sleep Disorders, Sleep Lab, Sleep Medicine
Obstructive sleep apnea - Consequences; Obstructive sleep apnea - Pathogenesis
Susheel P. Patil, MD, PhD is an Assistant Professor and Clinical Director of the Johns Hopkins Sleep Medicine Program. Dr. Patil received his undergraduate degree from Pennsylvania State University. Subsequently, he graduated with his medical degree from Jefferson Medical College prior to pursuing training in Internal Medicine at Case Western Reserve University (University Hospitals of Cleveland). Following a year as Chief Resident at Case Western, Dr. Patil came to Johns Hopkins for fellowship training in Pulmonary and Critical Care Medicine, during which he also completed training in Sleep Medicine. Dr. Patil also received a PhD in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health. He is board certified in Sleep Medicine, as well as Pulmonary and Critical Care Medicine.
Dr. Patil has been active in numerous committees and leadership roles in the Sleep and Respiratory Neurobiology Assembly of the American Thoracic Society and the American Academy of Sleep Medicine, and the American College of Chest Physicians. He has organized or spoke in numerous scientific symposia at the international meetings related to sleep medicine. He is the author of more than 30 publications, and has given invited lectures throughout the US. He is the Associate Director of the ACGME Sleep Fellowship at Johns Hopkins. Dr. Patil is also active in sleep medicine related public policy at the state level with roles in the Maryland Sleep Society and Chair of the Polysomnography Practice Committee of the Maryland Board of Physcians.
Dr. Patil has a longstanding interest in the pathogenesis of obstructive sleep apnea, particularly examining the relationship of obesity, inflammation, and adipokines to mechanical and neuromuscular factors that contribute to upper airway collapsibility. This has involved research studies involving bariatric surgery, HIV-infected, and non-alcoholic fatty liver disease patient groups affected by OSA. More recently he has been involved in clinical trials examining the effects of therapy on the cardiovascular consequences of OSA.